{"id":144238,"date":"2022-08-16T04:24:41","date_gmt":"2022-08-16T09:24:41","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2022\/08\/time-may-be-running-out-for-anti-aging-biotech-agex-as-funds-dry-up"},"modified":"2022-08-16T04:24:41","modified_gmt":"2022-08-16T09:24:41","slug":"time-may-be-running-out-for-anti-aging-biotech-agex-as-funds-dry-up","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2022\/08\/time-may-be-running-out-for-anti-aging-biotech-agex-as-funds-dry-up","title":{"rendered":"Time may be running out for anti-aging biotech AgeX as funds dry up"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/time-may-be-running-out-for-anti-aging-biotech-agex-as-funds-dry-up.jpg\"><\/a><\/p>\n<p>AgeX Therapeutics, a preclinical biotech looking to turn back the clock on aging, may have to wind down, announcing \u201csubstantial doubt\u201d about its ability to continue as money runs dry and debts mount.<\/p>\n<p>The California biotech made $12,000 in revenue for the second quarter and recorded $1.6 million in operating expenses over the same period, according to financial results <a href=\"https:\/\/www.businesswire.com\/news\/home\/20220812005093\/en\/AgeX-Therapeutics-Reports-Second-Quarter-2022-Financial-Results\">posted<\/a> August 12.<\/p>\n<p>During the first quarter, the biotech borrowed the final half million of credit available under a 2020 agreement with Juvenescence\u2014a separate anti-aging biotech\u2014and entered a new deal in which Juvenescence will provide $13.2 million in credit for a year. AgeX drew an initial $8.2 million of the line of credit and used $7.2 million to refinance the principal and the loan origination fees under a 2019 loan agreement with Juvenescence.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AgeX Therapeutics, a preclinical biotech looking to turn back the clock on aging, may have to wind down, announcing \u201csubstantial doubt\u201d about its ability to continue as money runs dry and debts mount. The California biotech made $12,000 in revenue for the second quarter and recorded $1.6 million in operating expenses over the same period, [\u2026]<\/p>\n","protected":false},"author":556,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,45,269],"tags":[],"class_list":["post-144238","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-finance","category-life-extension"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/144238","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=144238"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/144238\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=144238"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=144238"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=144238"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}